Biotron Limited
A.B.N. 60 086 399 144

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: mmora@miscorp.com.au
Website: www.biotron.com.au

14 September 2026

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

Resignation of Managing Director / CEO

- Dr Michelle Miller will step down as Managing Director and Chief Executive Officer for personal reasons after 24 years of service to Biotron.
- The Board thanks Dr Miller for her leadership and significant contribution to the Company since 2002 and acknowledges her role in advancing Biotron's strategic and clinical development.
- The Board has commenced a search process for new leadership effective immediately.

Biotron Limited (ASX: BIT) (**Biotron** or the **Company**) today announced that Dr Michelle Miller will step down as Managing Director and Chief Executive Officer, effective immediately, for personal reasons, after 24 years of service to the Company.

Dr Miller has agreed to remain available to assist with the transitioning to new leadership and to support the Company on matters that may benefit from her long tenure as CEO.

This announcement has been authorised for release to the market by the Board of Directors.

Yours sincerely

Marcelo Mora
Company Secretary

pjn13009

Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**Biotron Limited**
ABN	**60 086 399 144**

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Dr Michelle Miller
Date of last notice	23 December 2025
Date that director ceased to be director	14 September 2026

Part 1 – Director's relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
5,300,000 fully paid ordinary shares and 662,500 listed options (expiring 24 November 2027).

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	**Number & class of securities**
Michelle Miller + Peter Clarke <Miller Clarke Super Fund A/C> in which Michelle Miller has a beneficial interest	4,800,000 ordinary shares. 600,000 listed options (expiring 24 November 2027).

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.